BMC Medical Ethics 19 (1):1-10 (2018)

Authors
Cory E. Goldstein
University of Western Ontario
Abstract
Background Pragmatic randomized controlled trials are designed to evaluate the effectiveness of interventions in real-world clinical conditions. However, these studies raise ethical issues for researchers and regulators. Our objective is to identify a list of key ethical issues in pragmatic RCTs and highlight gaps in the ethics literature. Methods We conducted a scoping review of articles addressing ethical aspects of pragmatic RCTs. After applying the search strategy and eligibility criteria, 36 articles were included and reviewed using content analysis. Results Our review identified four major themes: 1) the research-practice distinction; 2) the need for consent; 3) elements that must be disclosed in the consent process; and 4) appropriate oversight by research ethics committees. 1) Most authors reject the need for a research-practice distinction in pragmatic RCTs. They argue that the distinction rests on the presumptions that research participation offers patients less benefit and greater risk than clinical practice, but neither is true in the case of pragmatic RCTs. 2) Most authors further conclude that pragmatic RCTs may proceed without informed consent or with simplified consent procedures when risks are low and consent is infeasible. 3) Authors who endorse the need for consent assert that information need only be disclosed when research participation poses incremental risks compared to clinical practice. Authors disagree as to whether randomization must be disclosed. 4) Finally, all authors view regulatory oversight as burdensome and a practical impediment to the conduct of pragmatic RCTs, and argue that oversight procedures ought to be streamlined when risks to participants are low. Conclusion The current ethical discussion is framed by the assumption that the function of research oversight is to protect participants from risk. As pragmatic RCTs commonly involve usual care interventions, the risks may be minimal. This leads many to reject the research-practice distinction and question the need for informed consent. But the function of oversight should be understood broadly as protecting the liberty and welfare interest of participants and promoting public trust in research. This understanding, we suggest, will focus discussion on questions about appropriate ethical review for pragmatic RCTs.
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1186/s12910-018-0253-x
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 71,355
Through your library

References found in this work BETA

What Should Be Disclosed to Research Participants?David Wendler - 2013 - American Journal of Bioethics 13 (12):3-8.

View all 16 references / Add more references

Citations of this work BETA

Randomised Controlled Trials in Medical AI: Ethical Considerations.Thomas Grote - forthcoming - Journal of Medical Ethics:medethics-2020-107166.

Add more citations

Similar books and articles

Ethical Issues of Randomized Controlled Trials.Jyotirmoy Sarker - 2014 - Bangladesh Journal of Bioethics 5 (1):1-4.
Ethical Argumentation.Douglas N. Walton - 2003 - Lexington Books.

Analytics

Added to PP index
2018-02-28

Total views
29 ( #396,803 of 2,519,513 )

Recent downloads (6 months)
2 ( #271,332 of 2,519,513 )

How can I increase my downloads?

Downloads

My notes